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Objectives: Fidaxomicin was non-inferior to vancomycin with respect to clinical cure rates in the treatment of
Clostridium difficile infections (CDIs) in two Phase III trials, but was associated with significantly fewer recur-
rences than vancomycin. This economic analysis investigated the cost-effectiveness of fidaxomicin compared
with vancomycin in patients with severe CDI and in patients with their first CDI recurrence.
Methods: A 1 year time horizon Markov model with seven health states was developed from the perspective of
Scottish public healthcare providers. Model inputs for effectiveness, resource use, direct costs and utilities were
obtained from published sources and a Scottish expert panel. The main model outcome was the incremental
cost-effectiveness ratio (ICER), expressed as cost per quality-adjusted life year (QALY), for fidaxomicin versus
vancomycin; ICERs were interpreted using willingness-to-pay thresholds of £20000/QALY and £30000/QALY.
One-way and probabilistic sensitivity analyses were performed.
Results: Total costs were similar with fidaxomicin and vancomycin in patients with severe CDI (£14515
and £14344, respectively) and in patients with a first recurrence (£16535 and £16926, respectively).
Improvements in clinical outcomes with fidaxomicin resulted in small QALY gains versus vancomycin (severe
CDI, +0.010; patients with first recurrence, +0.019). Fidaxomicin was cost-effective in severe CDI (ICER
£16529/QALY) and dominant (i.e. more effective and less costly) in patients with a first recurrence. The probabil-
ity that fidaxomicin was cost-effective at a willingness-to-pay threshold of £30000/QALYwas 60% for severe CDI
and 68% in a first recurrence.
Conclusions: Fidaxomicin is cost-effective in patients with severe CDI and in patients with a first CDI recurrence
versus vancomycin.
Keywords: economic, model, antibacterials
Introduction
For the past 30 years, the antibiotic treatment of Clostridium dif-
ficile infection (CDI) has depended primarily onmetronidazole and
vancomycin. Both agents are recommended in the current treat-
ment guidelines issued by the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID): oral metronida-
zole for initial non-severe episodes (evidence A-I); and oral vanco-
mycin for initial severe episodes (A-I), non-severe episodes (B-I),
first recurrence or those at risk of recurrent CDI (B-I) and multiple
recurrent episodes (B-II).1 The need for new treatment options
has become more pressing as the incidence and severity of CDI
has increased over the last decade in Europe and North
America.2,3 Additionally, the attendant economic consequences
of CDI in Europe are also significant4 with hospital bed-days, the
primary cost driver, accounting for up to 94% of expenditure.5
Therefore, the fiscal impact of any new therapies on healthcare
resource use is also worthy of consideration.
Fidaxomicin (DificlirTM; Astellas) is a narrow-spectrum oral
macrocyclic antibiotic for the treatment of CDI. It is minimally
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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absorbed from the gastrointestinal tract and achieves mean
faecal concentrations that exceed the MIC for C. difficile by
.5000-fold.6 Fidaxomicin is bactericidal against C. difficile7 and
inhibits spore production,8 but has minimal effect on the normal
gut microflora.9 In two Phase III randomized controlled trials in
patients with CDI, fidaxomicin was non-inferior to vancomycin
with respect to clinical cure rates, but was associated with signifi-
cantly fewer disease recurrences, which resulted in clinically
meaningful improvements in sustained clinical cure (i.e. clinical
cure without recurrence).10,11 Fidaxomicin is now recommended
in the European treatment guidelines for use in non-severe epi-
sodes (B-I), first recurrence or those at risk of recurrent CDI (B-I)
and for multiple recurrent episodes (B-II).1
It is becoming increasingly common for payers, managed care
organizations and regulatory bodies to demand health economic
analyses to assess the fiscal value of new pharmaceuticals.
Economic analyses allow the comparison of different treatments
in terms of clinical outcomes and costs and assist with decisions
regarding purchasing, pricing, reimbursement and formulary
acceptance. To date, the only published cost-effectiveness ana-
lyses involving fidaxomicin have been performed from a US
payer perspective.12,13
The present paper describes the outcomes from a cost-
effectiveness analysis of fidaxomicin versus vancomycin in patients
with CDI from the perspective of the National Health Service (NHS)
Scotland and Personal and Social Services in Scotland. It aims to
provide a cost-effectiveness model more relevant to European
healthcare systems. Given that the fidaxomicin Phase III trials10,11
suggest that patients with severe CDI and patients with a recur-
rence are likely to derive the greatest benefit from fidaxomicin in
terms of reducing recurrences, the present analysis focused on
these two patient subgroups. These subgroups are recognized as
identifiable patient subgroups in the real-world clinical setting and
are defined in the ESCMID guidelines.1 An indirect comparison of the
clinical effectiveness of fidaxomicin, vancomycin andmetronidazole
will be published separately as a companion article.14
Methods
Model overview
A decision-analytical framework was used for the cost-effectiveness ana-
lyses as it provides amethod for decisionmaking when there is uncertainty.
Specifically, a time-dependentMarkovmodel, which offers tractability in the
specification of the decision problem, i.e. the key health states related to the
disease, transition probabilities and associated cost and health outcomes,
was developed in ExcelTM (Microsoft Corp., Redmond, WA, USA) (Figure 1).
The Markov model consisted of seven different health states as defined in
Table 1.
The model evaluated the cost-effectiveness of fidaxomicin compared
with vancomycin in adults with severe CDI and patients with their first CDI
recurrence. The model was conducted from the perspective of the NHS
and Personal and Social Services in Scotland and considered directmedical
costs. The purpose of the model was to be submitted as part of the fidax-
omicin health technology assessment to the Scottish Medicines
Consortium. The model cycle length was 10 days, in line with the duration
of CDI treatment in clinical trials and clinical practice. As patients with CDI
can have multiple recurrences,15 it was decided to set the time horizon of
the model at 1 year. No discounting was applied to costs or outcomes
because of the 1 year time horizon.
Irrespective of whether the patient had severe CDI or a first recurrence,
the patient entered the model in the ‘CDI’ health state and was treated
either with oral fidaxomicin or oral vancomycin for 10 days. Successfully
treated patients entered and remained in the ‘CDI cured’ health state
unless they died due to any cause (age-matchedmortality) or experienced
a recurrence. If a patient had a recurrence, they then moved back to the
‘CDI’ health state and were treated again with the initial treatment.
In order to keep track of the severity and number of recurrences, the
‘CDI’ health state was split into five separate health states: (i) index CDI epi-
sode; (ii) first non-severe recurrence; (iii) first severe recurrence; (iv) second
or more non-severe recurrence; and (v) second or more severe recurrence.
In the fidaxomicin arm, the health state ‘CDI cured after failure’ for
patients initially on fidaxomicin who failed with initial treatment but
were cured after second- or third-line treatment was also considered.
Patients who did not respond to treatment progressed towards CDI
with complications or without. The CDI complications included in the
model were toxic megacolon, colonic perforation, sepsis or colectomy.
Drug-related adverse events from fidaxomicin or vancomycin were not
modelled as they were generally mild and would not lead to additional
treatment costs or a switch in treatment.
Irrespective of whether the patient had a complication or not, all
patients who failed to respond to fidaxomicin or vancomycin after
10 days were then treated with 250 mg of oral vancomycin four times
daily. If the patient was still not cured after 10 days of treatment with
250 mg of vancomycin four times daily, the dose was increased to
500 mg four times daily. In the event the patient also failed to respond
to 500 mg of vancomycin four times daily, they were then treated with
a vancomycin taper regimen. These patients remained in the ‘CDI
failed—vancomycin taper’ health state for 8 weeks, after which if the
patient did not respond they then received a last-resort adjunctive treat-
ment, which was assumed to be either an immunoglobulin infusion or a
14 day rifampicin course. Unless the patient died due to CDI, this
last-resort therapy was assumed to be successful and patients moved
to the ‘CDI cured’ health state after 60 days (six cycles of 10 days). No
patient was assumed to undergo surgery, based on advice from Scottish
experts that surgery for CDI is very rare in Scotland.
Inputs for effectiveness data, costs and utilities were extracted from
published sources and are described in detail below. Additional input
was sought from a group of Scottish clinical experts for parameters for
which data were limited, i.e. local treatment pathway and type of hospital
ward (clinician and microbiologist input), recovery of quality of life (QoL)
after CDI (health economics expert). The Scottish clinical expert panel
included a consultant microbiologist with NHS Greater Glasgow & Clyde,
a consultantmicrobiologist at NHS Ayrshire & Arran, an infectious diseases
consultant physician at NHS Tayside, an infectious diseases expert from a
Scottish university and a health economics expert from a Scottish univer-
sity. All the experts were paid a fee for service by Astellas for their time
attending the advisory board and none was an employee of Astellas.
Patient groups
Two patient subgroups were considered in the model: adults (aged
≥18 years) with severe CDI and adults with a first CDI recurrence.
Patients with a first recurrence (severe or non-severe) were defined as
those with a recurrence treated in hospital (also see the Recurrence and
reinfection section). Severe CDI was defined as in the fidaxomicin Phase
III studies, i.e. .15000 white blood cells/mm3, serum creatinine concen-
tration .1.5 mg/dL, or body temperature .38.58C,10 or ≥10 unformed
bowel movements/day or white blood cell count ≥15001/mm3.11
Treatment pathway
In the model, patients presenting with severe CDI or a first CDI recurrence
were treated initially with 200 mgof oral fidaxomicin twice daily for 10 days
or 125 mg of oral vancomycin four times daily for 10 days (Figure S1, avail-
able as Supplementary data at JACOnline). Vancomycinwas selected as the
comparator treatment based on current treatment guidelines in Scotland,
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which recommend oral vancomycin for any severe CDI episode16,17 and any
non-severe recurrence.16 According to clinical expert opinion, vancomycin
slurry is not prescribed in clinical practice in Scotland; therefore, only vanco-
mycin oral capsules were considered in the model.
In order to be consistent with Scottish treatment guidelines,16,17 it was
also assumed that first non-severe recurrences were treated with 450 mg
of oral metronidazole three times daily for 10 days. The dose selected for
oral metronidazole was the mean of the doses recommended in Scotland
(40016,17 and 500 mg16).
Patients who failed to respond to fidaxomicin or vancomycin were then
assumed to receive the following sequence of treatments, based on input
from the Scottish clinical experts, until a response was achieved: 250 mg
of oral vancomycin four times daily for 10 days; 500 mg of vancomycin
four times daily for 10 days; vancomycin taper regimen for 8 weeks; and
an adjunctive last-resort treatment (i.e. immunoglobulin infusion18 or
14 day rifampicin course). We did not include faecal transplantation19 as
an option in ourmodel as it is not awidely available treatment in Scotland.
Model assumptions
The assumptions made in the model and the justification for them are
summarized in Table S1 (available as Supplementary data at JAC
Online).1,10,11,14–17,20–24
Fail
Die
Live
Die
Live
Die
Live
Die
Live
Die
Live
Die
Live
Fail
Fail
Success
Success
Success
Fail
Success
CDI
CDI cured
CDI cured
after failure
CDI tx failed—VAN
250 mg
CDI tx failed—VAN
500 mg
CDI failed
VAN taper
Vancomycin
Fidaxomicin
Patient with severe
CDI or first CDI
recurrence
Death
Recurrence
Recurrence
No recurrence
No recurrence
Death
Death
Death
Death
Death
Death
CDI cured
CDI tx failed—VAN 250 mg
CDI tx failed—VAN 250 mg
CDI cured after failure
CDI cured after failure
CDI cured after failure
CDI cured after failure
CDI cured after failure
Continue taper
regimen
Last-resort therapy
CDI tx failed—VAN 500 mg
CDI failed VAN taper
CDI failed VAN taper
Assumed tx success
CDI
CDI cured
CDI
Complication
No complication
L
M
M +
Figure 1. Markovmodel structure. Definitions of transition states are provided in Table 1. Note: expandedmodel details shown for fidaxomicin arm only.
tx, treatment; VAN, vancomycin.
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Model input parameters
Clinical effectiveness
A summary of model effectiveness input parameters and the range of
values applied in the one-way sensitivity analysis is provided in
Table 2.10,14,15,24–27 Model inputs for clinical cure and recurrence rates up
to day 15 from end of treatment (EOT) were based on a pooled analysis14
of the intent-to-treat populations from the two Phase III randomized con-
trolled trials that compared fidaxomicin with vancomycin in patients with
CDI. Inputs for clinical cure and recurrence rates for metronidazole were
based on a randomized, double-blind comparison of metronidazole and
vancomycin in patients with CDI;25 since the clinical cure and recurrence
rates were not significantly different between treatments in patients with
non-severe CDI,25 we assumed that the odds ratio (OR) for both outcomes
was 1.0 for non-severe CDI episodes. The ranges of ORs tested in the one-
way sensitivity analysis were based on the 95% CIs of these ORs.
The base-case CDI-attributable mortality rate was estimated from a
literature review.24 The rate of background mortality was estimated
from the Scottish Decennial Life Tables 2000–02 for an average patient
in the pooled fidaxomicin studies (i.e. 62 years of age).27
Recurrence and reinfection
For the simplified purpose of themodel, patients could either have a recur-
rence or reinfection based on the two Phase III trials.10,11 Both health out-
comes incurred the same costs and if patients experienced either, they
moved into the ‘CDI’ recurrence health state.
A recurrence was defined as follows: the reappearance of more than
three diarrhoeal stools per 24 h period within 30 days of treatment com-
pletion; the presence of C. difficile toxin A, B or both in the stools; and the
need for retreatment for CDI following resolution of diarrhoea (i.e. three or
fewer diarrhoeal stools per day for 2 days consecutively, maintained for
the duration of initial treatment and no further need for treatment as of
the second day after the last dose of initial treatment).10,11 Since the fidax-
omicin Phase III studies had a total follow-up period of 30 days and data
for only one recurrence were available, data from Fekety et al.15 were used
to estimate the risk of multiple recurrences. Given the substantial reduc-
tion in the risk of recurrences observed with fidaxomicin, we assumed
that the treatment effect of fidaxomicin was maintained irrespective of
the number of previous recurrences.
The model did not distinguish between recurrences and reinfection:
any recurrence of CDI was modelled. It was assumed that 30 days after
the EOT, the chance of a recurrence was reduced. CDI recurrences occur-
ring after day 30 of EOT were assumed to be reinfections.23 At the time of
model construction, there were no data available on the risk of reinfection
in patients who had already experienced at least one CDI episode. It was
assumed, based on the evidence from Barbut et al.,23 that CDI episodes
occurring.2 weeks after successful treatment were likely to be a reinfec-
tion. The recurrence rate (8.4%) observed beyond day 15 of EOT in the
fidaxomicin Phase III trials was considered to be the rate of reinfection
(Astellas, data on file). It was assumed that the reinfection risk was the
same for fidaxomicin and vancomycin.
As the Phase III trials only provided data up to day 30 after EOT,
assumptions were made regarding reinfection after day 30. The model
made a conservative assumption on reinfection after day 40, in that it
was based on the recurrence rate reported in the vancomycin arm
between days 15 and 30 in the trial. The reinfection rate for fidaxomicin
and vancomycin was assumed to be the same and was set at 2.87%
per 10 day cycle in the model. This is a conservative assumption, as it is
now known that fidaxomicin has a lower reinfection rate than vancomy-
cin.28 Themodel assumes that patients in the ‘CDI cured’ health state after
day 40 can still have a reinfection, although in the model those patients
with a reinfection go into the ‘CDI’ health state and no differentiation is
made between recurrence and reinfection.
Resource use
A summary of inputs for resource use and the range of values applied in
the one-way sensitivity analysis are provided in Table 3. Estimates for
resource use were adjusted according to disease severity. For the base-
case analysis, 12.2% of recurrences were assumed to be severe.20
Patients with severe CDI (index episode or recurrence) were assumed
to be treated in hospital. For inpatients, the duration of hospitalization
depends on the underlying disease. Therefore, only excess hospitalization
due to CDI was considered in the model. Hospital Episode Statistics data
(for England and two Scottish health boards) show a mean excess length
of stay (LOS) of 19.3 days for an index episode of CDI and 12.2 days for a
recurrence when compared with healthcare resource group-matched
patients (Hospital Episode Statistics for C. difficile spells in 2010–11,
data on file). Limited information is available on the ward where patients
are hospitalized; however, according to Scottish clinical expert opinion,
70% of patients are in an isolated/side room in a general ward, 30% in
an infectious diseases unit or similar isolation room and only a few
patients require intensive care unit (ICU) admission. For the base-case
scenario, all hospitalized patients were assumed to be in an isolated
room in a general ward and the proportion of patients hospitalized in an
Table 1. Model health states
Health state Description
CDIa index CDI episode and any subsequent recurrent CDI episodes; all patients enter the model in this health state
CDI cured patient clinically cured after initial treatment
CDI cured after failure patient clinically cured after initial treatment failure
CDI tx failed—VAN 250 mg patient who failed to experience a clinical cure after fidaxomicin or vancomycin for 10 days and therefore
received treatment with 250 mg of vancomycin qid for 10 days
CDI tx failed—VAN 500 mg patient who failed to experience a clinical cure after 250 mg of vancomycin qid for 10 days and therefore
received 500 mg of vancomycin qid for 10 days
CDI failed—VAN taper patient who failed to experience a clinical cure after 500 mg of vancomycin qid for 10 days and therefore
received a vancomycin taper regimen for 8 weeks
Death patient who died due to either CDI or an unrelated cause
qid, four times daily; tx, treatment; VAN, vancomycin.
aIn order to keep track of the severity and number of recurrences, this health state was split into five separate tunnel states: index CDI episode; first
non-severe recurrence; first severe recurrence; second or more non-severe recurrence; and second or more severe recurrence.
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Table 2. Model inputs: effectiveness
Variable description
Base-case
inputa
Range for sensitivity analysisa
Uncertainty distribution Source(s)minimum maximum
OR for clinical cure in severe CDI treated with fidaxomicin 1 0.502 1.465 log normal (mean¼0.86;
SD¼0.273)
14
OR for clinical cure in CDI recurrence treated with fidaxomicin 1 0.415 2.808 log normal (mean¼1.08;
SD¼0.488)
14
OR for clinical cure in non-severe CDI (first recurrence) treated with
metronidazole
1 0.030 2.220 log normal (mean¼0.24;
SD¼1.10)
25
Clinical cure in severe CDI treated with vancomycin 0.853 0.802 0.897 b (n¼180; N¼211) 14
Clinical cure in CDI recurrence treated with vancomycin 0.889 0.817 0.945 b (n¼80; N¼90) 10
OR for recurrence in severe CDI treated with fidaxomicin 0.456 0.264 0.788 log normal (mean¼0.46;
SD¼0.279)
14
OR for recurrence in any CDI recurrence treated with fidaxomicin 0.528 0.256 1.086 log normal (mean¼0.53;
SD¼0.368)
14
OR for recurrence in any CDI recurrence treated with metronidazole 1 0.264 10.37 none 25
OR for CDI recurrence patients with ≥2 recurrences with fidaxomicin
versus vancomycin
0.528 0.256 1.00 none 14,15
OR for recurrence in patients with ≥2 previous recurrences 3.87 1.12 13.34 log normal
(mean¼1.35; SD¼0.63)
15
Recurrence rate in severe CDI treated with vancomycin 0.267 (0.098) 0.205 (0.073) 0.333 (0.126) b (n¼48; N¼180) 14
Recurrence rate in patients with a recurrence treated with vancomycin 0.325 (0.123) 0.227 (0.082) 0.431 (0.171) b (n¼26; N¼80) 14
Reinfection rate (recurrence 30 days after EOT) 0.084 (0.029) 0.059 (0.000) 0.113 (0.392) b (n¼33; N¼394) Astellas, data on file
Probability of a complication with fidaxomicin or vancomycin
(all CDI subgroups)
0.003 0.001 0.024 b (n¼4; N¼1147) Astellas, data on
file; 26
CDI-attributable mortality (30 day) 0.060 (0.020) 0.056 (0.002) 0.064b (0.002) b (n¼657; N¼10975) 24
Annual all-cause mortality 0.013 (0.0004) 0.000 (0.000) 0.090 (0.033) none 27
n, number of patients; N, total number of patients.
aNumbers in brackets refer to 10 day probabilities, where applicable.
bThe maximum 30 day mortality rate for severe CDI was considered to be 0.42 (0.105).
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infection isolation room was varied in the one-way sensitivity analysis
(range: 0%–20%). It was assumed that 7.7% of patients stayed in an
ICU/high-dependency unit for 20.4% of their excess LOS due to CDI
(Hospital Episode Statistics for C. difficile spells in 2010–11, data on file).
The excess stay in the ICU for these patients was estimated to be
2.2 days.29
Patients with non-severe recurrences were assumed to be treated in
the community unless the recurrence occurred in hospital, in which case
the patient was assumed to remain in hospital with a prolonged stay. It
was estimated that two-thirds of patients with non-severe recurrences
experienced their recurrence in hospital. Non-severe recurrences treated
in the community were assumed to require one general practitioner (GP)
visit at home and one GP visit at a primary care centre.
Costs
Direct costs only were considered in themodel, which included drug acqui-
sition and medical costs (i.e. hospitalization, complications and GP visits).
All cost inputs were extracted from public data or published literature and
presented in 2010/11 British pounds sterling (GBP, £). A summary of the
costs used in the model is provided in Table 4.30–34
Unit costs for drugs were obtained from the British National Formulary.34
The cost of a room in a general wardwas £430.87 per day.32 The cost of
a visit to a GP centre was £53; this was the cost per clinic consultation last-
ing 17.2 min.31 The cost of a home visit was £120; this was the cost of a
visit lasting 23.4 min including travel time.31
The cost of a severe CDI complication was assumed to be the average
of the costs of the four complications considered in the model (i.e. toxic
megacolon, colonic perforation, sepsis or colectomy) using non-elective
inpatient Scottish tariffs.30 For the base case, the final cost was £9915.
Utilities
Utility estimates for CDI were based on the data from Slobogean et al.,35
which were 0.30 for the initial 7 days of CDI-attributable hospitalization,
0.34 for the following 23 days and 0.78 for the remaining model time
frame following cure (i.e. remainder of year). In the currentmodel, the dur-
ation of impact of CDI on QoLwas assumed to last 10 days, i.e. duration of
treatment. In agreement with Scottish clinical expert opinion, it was
assumed that a patient’s QoL started to improve as soon as their diarrhoea
resolved. Thus, in the base case, the following utilities were applied: 0.30
for the first 3 days of diarrhoea; 0.34 for the remaining 7 days of treat-
ment; and 0.78 for cured patients. For a severe recurrence, it was assumed
that the recovery would not be as rapid as in non-severe CDI, but that this
would take another 10 day cycle with a mid-point utility of 0.56 before
reaching the utility of a cured patient. The utility used for CDI-related com-
plications was 0.30. A summary of utility estimates used in the model and
the range of values applied in the one-way sensitivity analysis is provided
in Table 5.
Model outputs
Model outputs included cost and effectiveness outcomes for each
treatment, incremental cost and effectiveness and incremental cost-
effectiveness ratios (ICERs) for fidaxomicin versus vancomycin. ICERs were
expressed as cost per quality-adjusted life year (QALY) and the cost per
recurrence avoided. QALYs were estimated as the sum of the weighted
time spent in each cycle for the 1 year model time horizon. Willingness-
to-pay thresholds of £20000/QALY and £30000/QALY generally applied by
the UK National Institute for Health and Care Excellence36 were used to
interpret ICERs.
Sensitivity analyses
Extensive one-way sensitivity analyses were performed to test the robust-
ness of themodel results using realistic ranges for each parameter derived
from published sources and Scottish clinical expert opinion (Tables 2–5).
For parameters with a higher impact on the ICER, we performed a thresh-
old analysis to identify the values that would yield ICERs below the
£20000/QALY and £30000/QALY thresholds.
Table 3. Model inputs: resource use
Variable description
Base-case
input
Range for sensitivity
analysis
Uncertainty
distribution Source(s)minimum maximum
Excess LOS in general ward for index infection (days) 19.32 16.64 22.20 g (SD¼1.42) Hospital Episode Statistics, data
on file
Excess LOS in general ward for a recurrence (days) 12.24 9.83 14.91 g (SD¼1.30) Hospital Episode Statistics, data
on file
Patients hospitalized in ICU for index infection (%) 0.077 0 0.08 b (n¼2341;
N¼30265)
Hospital Episode Statistics, data on
file; Scottish clinical expert panel
Patients hospitalized in ICU for a recurrence (%) 0.077 0 0.08 b (n¼2341;
N¼30265)
Hospital Episode Statistics, data on
file; Scottish clinical expert panel
Patients hospitalized in isolated infectious
diseases ward (%)
0 0 0.2 none Scottish clinical expert panel
Patients hospitalized in isolated infectious
diseases ward for a recurrence (%)
0 0 0.2 none Scottish clinical expert panel
Probability that a non-severe recurrence within
30 days of the previous episode is treated in
hospital
0.67 0.50 1 b (n¼20; N¼30) Hospital Episode Statistics, data
on file
Probability that a severe recurrence after 30 days of
the previous episode is treated in hospital
1 0.12 1 b (n¼41; N¼336) Scottish clinical expert panel
n, number of patients; N, total number of patients.
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A probabilistic sensitivity analysis was also performed with 10000
Monte Carlo simulations. Input variables with uncertainties were allowed
to vary simultaneously according to pre-defined distributions (Tables 2–4).
The probability of fidaxomicin being cost-effective at the £30000/QALY
willingness-to-pay threshold was estimated.
Results
Base-case scenario
A summary of the total treatment costs and the results of the base-
case scenario over a 1 year time horizon are presented in Table 6.
According to the model, the rate of clinical cure at 1 year was
slightly higher with fidaxomicin than vancomycin in patients with
severe CDI (88.9% versus 86.7%, respectively) and in patients
with a first recurrence (88.2% versus 84.8%, respectively).
Fidaxomicin was also associated with fewer recurrences than
vancomycin in patients with severe CDI (1.369 versus 1.797 per
patient, respectively) and in patients with a first recurrence (1.593
versus 2.347 per patient, respectively) over the 1 year horizon.
The acquisition costs of fidaxomicin were 4.5-fold higher
than those of vancomycin, but were offset in both patient sub-
groups by the higher hospitalization costs of vancomycin.
Overall, total costs were similar with both treatments in patients
with severe CDI (fidaxomicin, £14515; vancomycin, £14344) and
in patientswith a first recurrence (fidaxomicin, £16535; vancomy-
cin, £16926).
Compared with vancomycin, fidaxomicin was associated with
a slightly higher mean number of QALYs over the 1 year time hori-
zon in patients with severe CDI (0.715 versus 0.705) and patients
with a first recurrence (0.711 versus 0.692). Therefore, fidaxomicin
was cost-effective in severe CDI with an ICER of £16529/QALYand
dominant versus vancomycin in patients with a recurrence (ICER
2£21079/QALY, i.e. more effective and less costly).
First-line administration of fidaxomicin was associated with a
reduction in the number of recurrences over 1 year in patients
with severe CDI (difference: 20.428) and in patients with a recur-
rence (difference:20.754) comparedwith vancomycin. The average
cost per recurrence avoided with fidaxomicin versus vancomycin
Table 4. Model inputs: costs
Variable description Base-case input (£)
Range for sensitivity analysis
Source(s)minimum maximum
Severe CDI complication 9915 0 16170 30
GP visit, clinic 53 not varied 31
GP visit, home 120 not varied 31
General ward (per day) 430.87 not varied 32
Infectious ward (per day) 606 not varied Scottish clinical expert panel
Intensive care (per day) 2044 not varied 32
Medication costs
fidaxomicin (200 mg bid, 10 days) 1350 not varied 33
metronidazole (450 mg tid, 10 days) 2.17 not varied 34
vancomycin (125 mg qid, 10 days)a 189 not varied 34
vancomycin (250 mg qid, 10 days)a 378 not varied 34
vancomycin (500 mg qid, 10 days)a 757 not varied 34
vancomycin taper regimenb 407 not varied 34
last-resort therapyc 397 397 11101 34
bid, twice daily; od, once daily; qid, four times daily; tid, three times daily.
aVancocinw 125 mg oral capsules.
bOral vancomycin at 125 mg qid for 14 days, then 125 mg bid for 7 days, then 125 mg od for 7 days and then 125 mg every 3 days for 28 days.
cSingle infusion of 250 mg/kg intravenous immunoglobulin or a 14 day course of 1200 mg/day oral rifampicin.
Table 5. Model inputs: utilities
Variable description Base-case input
Range for sensitivity
analysis
Uncertainty distribution Source(s)minimum maximum
CDI (initial 3 days of treatment) 0.30 0.10 0.50 normal (SD¼0.1) 35
CDI (days 7–10 of treatment) 0.34 0.14 0.54 normal (SD¼0.1) 35
Cured 0.78 0.58 0.98 normal (SD¼0.1) 35
Decrement for patients experiencing a serious complication 0 0 0.10 none assumption
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was £400 for patients with severe CDI and2£518 for patients with
a first recurrence.
One-way sensitivity analyses
The parameters to which the model was most sensitive were the
following: OR of experiencing a recurrence with fidaxomicin in
patients who had already experienced one, two or more recur-
rences; OR of experiencing a recurrence with fidaxomicin in
patientswith severe CDI; OR of having recurrent CDI; and the prob-
ability of a recurrence being treated in hospital.
The results of the threshold analysis performed to identify the
values that would yield an ICER below the £20000/QALY and
£30000/QALY thresholds are presented in Table 7. The probability
of having an ICER below £20000/QALY when varying any of the
aforementioned parameters ranged between 52% and 69% in
severe CDI and between 65% and 74% in patients with a first
recurrence.
The impact of the remaining parameters on the model was
small (Table S2, available as Supplementary data at JAC Online).
Probabilistic sensitivity analysis
In patients with severe CDI, the mean incremental cost for fidaxo-
micin versus vancomycin was 2£82 [standard deviation (SD):
£1325] and the incremental QALYs were 0.016 (SD: 0.008), yielding
Table 6. Base-case results over a 1 year time horizon
Severe CDI First CDI recurrence
vancomycin fidaxomicin vancomycin fidaxomicin
Average costs per patient at 1 year, £
medication acquisition 571 2567 800 3630
hospitalization 13600 11793 15928 12742
complications 11 11 13 10
GP visits 163 145 186 154
total 14344 14515 16926 16535
difference 171 2391
Clinical outcomes
cure, % 86.7 88.9 84.8 88.2
deaths, % 7.6 6.7 8.8 7.1
QALYs
mean QALYs 0.705 0.715 0.692 0.711
difference 0.010 0.019
Recurrences
recurrences, n 1.797 1.369 2.347 1.593
recurrences avoided, n 0.428 0.754
Cost-effectiveness outcomes
ICER, £ per QALY 16529 221079
cost per recurrence avoided, £ 400 2518
Table 7. Threshold analysis for key drivers in the model
Parameter
Base-case
value
Severe CDI First CDI recurrence
ICER
,£20000/QALY
ICER
,£30000/QALY
ICER
,£20000/QALY
ICER
,£30000/QALY
OR of experiencing a recurrence with fidaxomicin in patients
who have already a first or second recurrence
0.528 0.540 0.573 0.606 0.624
OR of experiencing a recurrence with fidaxomicin in patients
with ≥2 recurrences
0.528 0.540 0.576 0.642 0.665
OR of having recurrent CDI 3.87 3.760 3.450 2.78 2.59
OR of experiencing a recurrence with fidaxomicin in patients
with severe CDI
0.456 0.474 0.525 — —
Probability of a recurrence being treated in hospital 0.667 0.651 0.604 —a —a
aICER remained below threshold even at the lowest range tested.
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amean ICER of2£5066/QALY. In patients with first recurrence, the
mean incremental cost for fidaxomicin versus vancomycin was
2£1076 (SD: £2800) and incremental QALYs were 0.019 (SD:
0.014), yielding a mean ICER of 2£57354/QALY. The effect of this
uncertainty on the ICERs for fidaxomicin compared with vancomy-
cin in both patient subgroups is shown in Figure 2. The probability
that fidaxomicin was cost-effective at a willingness-to-pay thresh-
old of £30000/QALY was 60% for severe CDI and 68% for patients
with a first recurrence. The cost-effectiveness acceptability curves
for both patient subgroups are shown in Figure 3.
Discussion
We developed a decision-analytical model to assess the cost-
effectiveness of fidaxomicin compared with vancomycin in the
treatment of patients with severe CDI or a first recurrent episode
from the perspective of Scottish public healthcare providers. The
fidaxomicin Phase III trials indicate that 24%–39% of patients
with CDI have severe episodes and 15%–17% of patients have
first recurrences.10,11 Over a 1 year time horizon, the model
showed that patients with severe CDI had 1.8 and 1.4 recurrences
if treated with vancomycin and fidaxomicin, respectively, and that
following a first CDI recurrence, patients had 2.4 and 1.6 add-
itional recurrences with vancomycin and fidaxomicin, respect-
ively. The model did not differentiate between relapses and
reinfection and, 30 days after EOT, the probability of reinfection
was assumed to be equal in both arms. This assumption was
made based on the best evidence available at the time of
model development, although recent clinical data suggest that
this underestimates the reduction in recurrences with fidaxomi-
cin.28 However, evenwith this conservative assumption, fidaxomi-
cin is still a cost-effective treatment option for the patient
subgroups analysed. The opportunity to develop the model with
more accurate long-term relapse and reinfection data will be pos-
sible when long-term effectiveness data for fidaxomicin are avail-
able. The resulting downstream savings in direct medical costs
meant that the acquisition cost of fidaxomicin was almost com-
pletely offset by lower hospitalization costs. The base-case ana-
lysis showed that fidaxomicin was cost-effective in patients with
severe CDI (ICER: £16529/QALY) and dominant versus vancomy-
cin in patients with a first recurrence (2£21079/QALY, i.e. more
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Figure 2. Probabilistic sensitivity analysis: ICER scatter plots for patients
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effective and less costly). The average cost per recurrence avoided
was £400 for fidaxomicin versus vancomycin in patients with
severe CDI and was cost saving (by £518) in patients with a first
recurrence. These are important cost-effectiveness data for fidax-
omicin in the treatment of CDI from a UK and NHS perspective.
Our findings complement and support recent cost-effectiveness
data from the USA12 and existing efficacy data10,11 and show
that, when costs are applied to the efficacy outcomes of fidaxo-
micin in terms of clinical cure and recurrence rates, this agent is
cost-effective versus standard therapy.
Extensive one-way and probabilistic sensitivity analyses were
conducted to evaluate the input parameters and assumptions
used in the model. The one-way sensitivity analysis showed that
the main drivers of cost-effectiveness were inputs relating to the
risk of recurrence with fidaxomicin. The larger the effect of fidax-
omicin in reducing the recurrence rate, the more cost-effective it
was. However, the ICERs for fidaxomicin consistently remained
below the £20000/QALYor £30000/QALY thresholds if the various
ORs for recurrence were varied over plausible ranges. These find-
ings support the robustness of the model findings.
Ourmodel is unique froma European healthcare perspective. By
using published data and advice from Scottish clinical experts, we
were able to develop a seven-state model that simulated the nat-
ural evolution of CDI. Since patients with severe CDI and most CDI
recurrences are treated with oral vancomycin in clinical practice,
vancomycin was selected as the comparator for the model.
Metronidazole was also included for non-severe recurrent episodes
in line with current Scottish guidelines,16,17 although the dose
applied (450 mg three times daily) was the mean of Scottish
recommendations16,17 and slightly lower than the European dose
(500 mg three times daily).1 A conservative approach was taken
in the model when there was uncertainty. For example, costs for
disinfection and ward closures, which would have favoured fidaxo-
micin due to its ability to decrease the recurrence rate, were omit-
ted. A conservative approach was also taken regarding the
hospitalization of patients with CDI. In the model, only severe epi-
sodes and non-severe CDI occurring in hospitalized patients had
costs for excess hospitalization. All other episodes, such as non-
severe recurrences, were treated in the community. The proportion
of patients requiring hospitalization in our model was driven by the
proportion of episodes expected to be severe, whichwas estimated
to be 12.2% for the base case;20 this is lower than in a recent UK
study, which reported that severe disease occurred in 20% of hos-
pitalized cases.37 We also assumed that all patients treated in hos-
pital were in a general ward. Local clinical experts suggested that
30% of inpatients are treated in an infectious diseases isolation
unit. In the sensitivity analysis, increasing the proportion of patients
treated in such rooms decreased the ICER in favour of fidaxomicin.
Themodel did not take into account the potential important role of
transmission of infection, although recent publications38,39suggest
that onward transmission within hospitals accounts for a relatively
small number of CDI cases detected. Furthermore, inclusion of
these data, and estimating their impact on cost, would require a
different modelling approach.
The key effectiveness inputs for the model were taken from a
pooled analysis of two large randomized Phase III studies com-
paring fidaxomicin with vancomycin in CDI;14 however, there
were some differences between the structure of the model and
the design of the clinical trials. For example, in the clinical trials,
patients were followed for up to 40 days if they had a successful
response to initial treatment and no recurrence or until they had a
recurrence. If the patient failed to respond to study treatment,
data collection was stopped after 10 days of treatment.
However, in clinical practice, patients who fail initial treatment
or who have a recurrence continue to be treated until a satisfac-
tory outcome is achieved. Therefore, it is not possible to ‘read
across’ from the clinical trial data to the results of our model,
because the cure rate in the model is based on up to four lines
of treatment rather than one, as in the clinical trial. The mortality
rates used in the model also differed slightly from those reported
in the clinical trials. We used the 30 day CDI-attributablemortality
rate (5.99%) reported by Karas et al.,24 which is amean value from
12 studies. These changes led to a higher clinical cure rate in both
arms of the economicmodel compared with the clinical trial data.
Additionally, the model predicted a numerical advantage in the
clinical cure rate for fidaxomicin over vancomycin both in severe
CDI and in patients with a first recurrence. Minor differences in
the recurrence rates were also noted, mainly because of differ-
ences in the mortality rates. However, the main differences
between the fidaxomicin clinical trials and the model affected
clinical cure rates. As clinical cure was not a major driver of the
economic results, as shown by the sensitivity analysis, we believe
that the implications of these differences are minimal.
Stranges et al.12 recently published a cost-effectiveness analysis
of fidaxomicin [marketed in the USA as DificidTM (Cubist)] versus
vancomycin for the treatment of CDI from a US payer perspective.
As in our analysis, the ICER (US$67576/QALY) was below the
accepted US willingness-to-pay threshold (US$100000/QALY).
However, there are several key differences between the two ana-
lyses. The base case of the US model considered all patients with
CDI, rather than specified subgroups as in ourmodel. The effective-
ness inputs in theUSmodelwere basedonlyon theNorth American
Phase III study,11 whereas the present paper used a pooled ana-
lysis of both the North American and European Phase III trials.14
The USmodel included up to three CDI episodes and then assumed
an average life expectancy of 23 years for surviving patients,
whereas the present model had a 1 year time horizon, which
allowed more CDI episodes to occur. These design differences
should be considered when comparing these findings.
When comparing the relative value of a novel treatment with
other common and effective healthcare preventative interven-
tions, the concept of ‘number needed to treat’ (NNT) is useful. A
recent analysis calculated that for every seven patients treated
with fidaxomicin, one hospital readmission for CDI is prevented
compared with vancomycin (i.e. NNT 7.1),40 which compares
very favourably to other common preventative healthcare inter-
ventions. For example, the use of aspirin following a myocardial
infarction has an NNT of 40 to prevent one death within
5 weeks.41 As such, judicious use of fidaxomicin in a specific popu-
lation at risk of recurrence is cost-effective and compares favour-
ably with many treatments currently regarded as standards
of care.
Our model was designed to reflect the clinical situation in
Scotland using relevant treatment guidelines and information
sources where available. The findings reported in this paper are,
therefore, directly relevant to the healthcare environment in
Scotland alone. However, as the Scottish treatment guidelines
for CDI16,17 are consistent with European guidelines (2009 ver-
sion),42 it is anticipated that the model structure will be broadly
applicable to other European countries, although adjustment of
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relevant costs and resource use data will be required for each
country.
To put the value of this analysis in a broader context, we need
to consider the emphasis currently placed within European
healthcare systems to reduce hospital admissions, readmissions
and overall LOS.43 Indeed, the cost to England of readmissions
has been estimated to be £2.3 billion and a range of measures
are being implemented to reduce these.44 For adults hospitalized
with CDI, 41% are readmitted within 90 days and 13% of these
patients develop recurrent CDI during readmission;45 therefore,
treatments that reduce recurrences, and thereby readmissions,
are welcomed.
In conclusion, this economic model suggests that fidaxomicin
is cost-effective in the treatment of patients with severe CDI and
in patients with a first recurrence of CDI when compared with
vancomycin. First-line administration of fidaxomicin in these
two patient subgroups may reduce the fiscal impact of CDI. Our
findings are likely to be of broader applicability to European
healthcare systems.
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